What does Somite AI do?
Somite AI leverages foundation models and proprietary AI to accelerate human cell therapy development. The company is building DeltaStem, a platform that uses proprietary capsule technology to generate cell state transition data and optimize the production of human cells.
How much did they raise?
The company raised an undisclosed amount in Series A funding. The round was led by Khosla Ventures with participation from SciFi VC, the Chan Zuckerberg Initiative, Fusion Fund, Ajinomoto Group Ventures, Pitango HealthTech, TechAviv, Harpoon Ventures, and angel investors such as Dr. R. Martin Chavez and Fidji Simo.
What are their plans for the money?
Somite AI intends to use the funds to accelerate key therapeutic programs, including beta cells for type 1 diabetes, articular cartilage for orthopedic applications, satellite cells for muscular diseases, and hematopoietic cells for blood disorders, while further developing its DeltaStem platform.
What have they achieved so far?
The company has already advanced its DeltaStem platform by generating cell state transition data that accelerates and optimizes the development of novel cell differentiation protocols.
